2Seventy Bio

TSVT · NASDAQ

Price unavailable right now.

No price history for this range.

TSVT analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated Nov 30, 2024

Bull case

2seventy bio Inc. demonstrates a strong potential for growth, particularly with its flagship therapy, Abecma, which exhibited a convincing progression-free survival (PFS) benefit over standard regimens, highlighting its efficacy in treating triple-class exposed relapsed or refractory multiple myeloma (r/r MM). Additionally, the favorable overall survival (OS) outcomes for patients who crossed over to Abecma treatment underscore the therapy's promising long-term benefits, which could enhance its market position amidst increasing competition. The recent expanded collaboration agreement suggests a positive trajectory for the company’s financial health and reinforces the belief in the transformative potential of its cell and gene therapies.

Bear case

2seventy Bio Inc faces significant risks that could hinder its financial performance, primarily stemming from lower than expected sales of its therapy ABECMA, which is perceived to have reduced efficacy compared to competing treatments for multiple myeloma. The company has also encountered challenges with its clinical pipeline, characterized by unexpected toxicities and a failure to develop early candidates, potentially indicating difficulties in addressing patient populations with more severe conditions. Additionally, the interpretability issues related to clinical data, particularly concerning crossover effects and the study's insufficient power, underscore uncertainties that could adversely impact investor confidence and future revenue projections.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.